Warning Letters Can Reduce Quetiapine Overprescribing
MONDAY, April 29, 2024 -- For patients with dementia, letters warning primary care physicians (PCPs) regarding overprescribing can reduce quetiapine prescriptions, according to a study published online April 25 in JAMA Network Open. Michelle... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 29, 2024 Category: Pharmaceuticals Source Type: news

Medicare Warnings Stop Nursing Homes From Overusing Antipsychotic Meds
FRIDAY, April 25, 2024 -- Warning letters sent by Medicare officials can prompt a decline in antipsychotic prescriptions for seniors with dementia, a new study finds.Letters sent to heavy prescribers of quetiapine (Seroquel), the most popular... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 26, 2024 Category: General Medicine Source Type: news

Severe QT Prolongation Common in Users of Antipsychotic Medications
TUESDAY, Jan. 23, 2024 -- More than one in eight patients receiving quetiapine or haloperidol therapy appear to develop severe QT prolongation (SQTP), according to a study published online Jan. 14 in Heart Rhythm.Chun-Li Wang, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 23, 2024 Category: Pharmaceuticals Source Type: news

Esketamine Bests Quetiapine for Resistant Depression Esketamine Bests Quetiapine for Resistant Depression
Intranasal esketamine (Spravato, Janssen) is superior to extended-release quetiapine (Seroquel, AstraZeneca) for treatment-resistant depression, results of a multicenter, head-to-head phase 3 trial show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 10, 2023 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Esketamine Nasal Spray Beneficial for Treatment-Resistant Depression
THURSDAY, Oct. 5, 2023 -- For patients with treatment-resistant depression, esketamine nasal spray is superior to extended-release quetiapine with respect to remission at week 8, according to a study published in the Oct. 5 issue of the New England... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 5, 2023 Category: Pharmaceuticals Source Type: news

Esketamine Tops Quetiapine in Treatment-Resistant Depression
(MedPage Today) -- Esketamine nasal spray (Spravato) led to better remission rates compared with extended-release quetiapine (Seroquel XR) in patients with treatment-resistant depression when used in combination with ongoing treatment, the randomized... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - October 5, 2023 Category: Psychiatry Source Type: news

Nasal esketamine works better than alternative for treatment-resistant depression, study finds
A nasal spray version of esketamine was more effective for depression that is resistant to treatment than a more commonly used drug, research published Wednesday in The New England Journal of Medicine found. Esketamine is a more potent form of ketamine, an anesthetic that doctors have used for…#spravato #africa #southamerica #michaelgrunebaum #newyorkcity #snri #seroquel #allanyoung #kingscollegelondon #amitanand (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2023 Category: Consumer Health News Source Type: news

Assessing Pain Among Individuals Living With Dementia
During the early days of the COVID-19 pandemic, I received a telephone call from a caregiver in an assisted living facility with a request to restart quetiapine for a male resident living with severe dementia and type 2 diabetes mellitus. This resident had been successfully tapered off quetiapine nine months earlier. Although he had a history of psychotic symptoms and physical aggression, he had been both medically and behaviorally stable. (Source: Caring for the Ages)
Source: Caring for the Ages - March 1, 2023 Category: Health Management Authors: Elizabeth Galik Tags: Caring Collaborative Source Type: news

Comparison of serum and whole blood concentrations in quetiapine overdose cases - Saito T, Tsuji T, Namera A, Morita S, Nakagawa Y.
This study aimed to compare whole blood and serum concentrations of quetiapine in acute poisoning cases. Authentic whole blood and respective serum samples were routinely collected from patients diagnosed with blood poisoning at our University Hospital. Ac... (Source: SafetyLit)
Source: SafetyLit - December 5, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Risk assessment of accidental falls in patients taking trazodone, quetiapine, or risperidone for insomnia: a single-center, case-control study - Shimizu Y, Taga M, Takahashi Y, Yamamoto Y, Masauji T.
In this study, we evaluated the risk of falls with trazodone, risperidone, and quetiapine, which are recommended for use at Kanaz... (Source: SafetyLit)
Source: SafetyLit - November 4, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Association between quetiapine use and self-harm outcomes among people with recorded personality disorder in UK primary care: a self-controlled case series analysis - Hayes JF, Hardoon S, Deighton J, Viding E, Osborn DP.
BACKGROUND: Quetiapine is frequently prescribed to people with personality disorder diagnoses, but this is not supported by evidence or treatment guidelines. AIMS: To examine associations between periods of quetiapine prescribing and self-harm events in pe... (Source: SafetyLit)
Source: SafetyLit - November 3, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Combined effects of quetiapine and opioids: a study of autopsy cases, drug users and sedation in rats - Andersen FD, Joca S, Hvingelby V, Arjmand S, Pinilla E, Steffensen SC, Simonsen U, Andersen CU.
This study aimed to elucidate if quetiapine, a widely used sedative antipsychotic medication, may increase the risk of fatal opioid poisoning by additive inhibitory effects on the central nervous... (Source: SafetyLit)
Source: SafetyLit - September 15, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Apotex Corp. Issues Voluntary Nationwide Recall of Guanfacine Extended-Release Tablets 2mg Due to Trace Amounts of Quetiapine Fumarate
Weston, Florida, Apotex Corp is voluntarily recalling three (3) lots of Guanfacine Extended-Release Tablets 2mg to the consumer level due to trace amounts of Quetiapine Fumarate in one lot RX1663. Out of an abundance of caution, lots RX1662 and RX1664 are also included in the scope of this voluntary (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 31, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Interaction of heavy drinking patterns and depression severity predicts efficacy of quetiapine fumarate XR in lowering alcohol intake in alcohol use disorder patients - Vatsalya V, Kong M, Marsano LM, Kurlawala Z, Chandras KV, Schwandt ML, Ramchandani VA, McClain CJ.
BACKGROUND: Shared etiological pathways of dopamine and serotonin neurotransmission play a central role in heavy alcohol intake and exacerbation in the symptoms of depression.We investigated the treatment efficacy of Quetiapine fumarate extended release (X... (Source: SafetyLit)
Source: SafetyLit - September 25, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Response to: the neuroprotective effect of quetiapine in critically-ill traumatic brain injury patients - Mitjans MS, Burry L, Williamson D.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - September 7, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news